ArticleIranian journal of microbiology2025
SARS-CoV-2 mRNA vaccine candidate encoding RBD chimera of Delta and Omicron variants: immunogenic potential and validation.
Article in Iranian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has presented a challenging issue for global health in the 21 Materials and Methods: We evaluated the uptake of mRNA-LNPs into human monocyte-derived dendritic cells by measuring the intensity of enhanced eGFP expression in the transfected cells. Next, we assessed the effect of mRNA-LNPs on immune response induction in mice following a prime-boost immunization strategy, along with analyzing cytokine release. The safety of the vaccine candidate was examined through pyrogenicity and toxicity assays. Results: Upon intramuscular injection of mice, potent antibodies specific to viral S protein, robust Th1-biased cell-mediated immunity, and enhanced IFN-γ expression were induced. These observations indicate that mRNA-LNP was taken up and that it migrated to the lymph nodes. Furthermore, the vaccine candidate did not cause inflammation or local reactions after injection, as confirmed by biochemical, hematological, and histopathological examinations. Conclusion: Because of its ability to target immune cells, the mRNA vaccine candidate can potentially improve immune responses against circulating or emerging variants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.